# Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

> **NCT03333694** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)

## Interventions

- **DRUG:** Cutaneous Cream application
- **DRUG:** Placebo Cutaneous Cream application

## Key facts

- **NCT ID:** NCT03333694
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-15
- **Primary completion:** 2018-11-01
- **Final completion:** 2018-11-01
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** The study fully enrolled and completed after last patient completed the study
- **Last updated:** 2020-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03333694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03333694, "Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03333694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*